Archives

Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

B – Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the… Login to continue reading Login…

Read MoreBambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

NAMSA and Lexitas Announce Strategic Partnership to Deliver End-to-End Ophthalmic Medical Device Development

B Sponsors gain a single, accountable partner through all stages of product development, with Lexitas’ dedicated ophthalmology expertise embedded in NAMSA’s end-to-end MedTech development platform… Login to continue reading Login…

Read MoreNAMSA and Lexitas Announce Strategic Partnership to Deliver End-to-End Ophthalmic Medical Device Development